Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation
About
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to the ongoing REDUCE-IT cardiovascular outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa, visit www.vascepa.com. For more information about
Availability of other information about
Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in
Investor Relations:
Kathryn McNeil
Investor Relations and Corporate Communications
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
Trout Group
In U.S.: +1 (646) 378-2954
gmorrell@troutgroup.com
Media Inquiries:
In U.S.: +1 (212) 583-2791
Kristie.kuhl@finnpartners.com
Source:
News Provided by Acquire Media